Publications

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, Zhang Y, Li T, Liu S, Zhang M, Zhao C, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Shi Y, Shen Y, Xie L, Zhang L, Qu X, Xu W, Huang W, Wang Y. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021 Apr 29;184(9):2362-2371.e9. doi: 10.1016/j.cell.2021.02.042. Epub 2021 Feb 23. PMID: 33735608; PMCID: PMC7901273.

Read more

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment

Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang, Zhenfei Li, Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment, Cell Reports Medicine, 2022, 100608, ISSN 2666-3791, https://doi.org/10.1016/j.xcrm.2022.100608.

Read more

Back to top